Erratum: Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial

被引：0
|
作者：
Wolfgang Gaebel
Andreas Schreiner
Paul Bergmans
Rosario de Arce
Frédéric Rouillon
Joachim Cordes
Lars Eriksson
Enrico Smeraldi
机构：
来源：
Neuropsychopharmacology | 2011年 / 36卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Correction to: Neuropsychopharmacology (2010) 35, 2367–2377; doi:10.1038/npp.2010.111; published online 4 August 2010 In this article, the authors would like to apologize for an error inadvertently introduced into the paper. During pre-marketing clinical studies, reactions that presented with signs and symptoms consistent with olanzapine overdose were reported in patients following an injection of olanzapine pamoate.
引用
收藏
页码：548 / 548
相关论文
共 50 条
  • [11] AN OPEN, RANDOMIZED, CONTROLLED COMPARISON OF LONG-ACTING INJECTABLE RISPERIDONE VS. ORAL OLANZAPINE IN SCHIZOPHRENIA & SCHIZOAFFECTIVE DISORDER
    Keks, Nicholas A.
    SCHIZOPHRENIA RESEARCH, 2012, 136 : S5 - S5
  • [12] Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder - Randomised, controlled, open-label study
    Keks, Nicholas A.
    Ingham, Michael
    Khan, Akbar
    Karcher, Keith
    BRITISH JOURNAL OF PSYCHIATRY, 2007, 191 : 131 - 139
  • [13] Functional recovery results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE)
    Rouillon, Frederic
    Eriksson, Lars
    Burba, Benjaminas
    Raboch, Jiri
    Kaprinis, Georgios
    Schreiner, Andreas
    ACTA NEUROPSYCHIATRICA, 2013, 25 (05): : 297 - 306
  • [14] Subjective attitude to risperidone long-acting injectable (RLAI): Results from a long-term Italian study in subjects with schizophrenia or schizoaffective disorder
    Rossi, A.
    Bernareggi, M. M.
    Giustra, M. G.
    EUROPEAN PSYCHIATRY, 2008, 23 : S167 - S167
  • [15] Obese patients with schizophrenia and schizoaffective disorder: Efficacy of injectable long-acting risperidone
    Permuy, RT
    Turner, MS
    Bouhours, P
    SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 175 - 175
  • [16] Descriptive analysis of the Aripiprazole arm in the Risperidone long-acting injectable vs. Quetiapine relapse prevention trial (constaTRE)
    de Arce, R.
    Eding, E.
    Marques, T.
    Milanova, V
    Rancans, E.
    Ibach, B.
    Schreiner, A.
    PHARMACOPSYCHIATRY, 2009, 42 (05) : 214 - 214
  • [17] Effectiveness of Switching From Long-Acting Injectable Fluphenazine or Haloperidol Decanoate to Long-Acting Injectable Risperidone Microspheres: An Open-Label, Randomized Controlled Trial
    Covell, Nancy H.
    McEvoy, Joseph P.
    Schooler, Nina R.
    Stroup, T. Scott
    Jackson, Carlos T.
    Rojas, Ingrid A.
    Essock, Susan M.
    JOURNAL OF CLINICAL PSYCHIATRY, 2012, 73 (05) : 669 - 675
  • [18] Randomized, placebo-controlled, long-term study of risperidone long-acting injectable in relapse prevention in bipolar I disorder patients
    Quiroz, J. A.
    Yatham, L. N.
    Palumbo, J. M.
    Karcher, K.
    Kushner, S.
    Kusumakar, V.
    BIPOLAR DISORDERS, 2009, 11 : 71 - 71
  • [19] Treatment of schizophrenia with long-acting injectable risperidone: A 12-month open-label trial of the first long-acting second-generation antipsychotic
    Fleischhacker, WW
    Eerdekens, M
    Karcher, K
    Remington, G
    Llorca, PM
    Chrzanowski, W
    Martin, S
    Gefvert, O
    JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (10) : 1250 - 1257
  • [20] A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia
    Fleischhacker, W. Wolfgang
    Gopal, Srihari
    Lane, Rosanne
    Gassmann-Mayer, Cristiana
    Lim, Pilar
    Hough, David
    Remmerie, Bart
    Eerdekens, Marielle
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 (01): : 107 - 118
12345